HCRT and schizophrenia: To the best of current knowledge, this is the first systematic review and meta-analysis that provides insight into investigating plasma orexin-A levels across patients with schizophrenia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD), synthesizing data from 11 studies involving 1,778 participants [11-13,18,25-31].